Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 221-240 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 221 | Payload Aerospace, S.A. lowweak | Opp 2 Risk 3 | Thesis: Only weak opportunity support is visible in these reviewed sources: membership rationale says the company completed a €180M Series C fundraising, but no representative article, no direct positive evidence, and no in-recent evidence window article detail are provided here, so there is not enough cited support to form a strong 1 year+ opportunity thesis. Why now: Why now is weak because the reviewed sources' coverage debug shows zero article IDs after the March 29, 2026 cutoff and zero evidence after recent evidence window; any older fundraising context may no longer capture current business state. See support references listing article in the membership rationale, but no or article detail is provided in the reviewed sources, so recency and context cannot be independently assessed. Caveats: No -bearing article detail is provided for the fundraising support article, so factual claims beyond the membership rationale cannot be expanded. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0, limiting confidence. |
| 222 | Pilot Photonics lowweak | Opp 2 Risk 1 | Thesis: Membership rationale says Pilot Photonics secured a €1 million ESA contract for space photonics development and that the technology addresses satellite communication demands, which could support a modest long-horizon opportunity thesis if contract execution expands. Why now: Why now is limited because only membership rationale references article: and the reviewed sources provide no or retained evidence after recent evidence window. Caveats: The ESA contract claim cannot be elevated strongly without the underlying article or summary in the reviewed sources. Coverage data shows evidence after recent evidence window 0. Opportunity may be real, but reviewed sources support is too sparse for higher conviction. |
| 223 | Pixxel lowweak | Opp 2 Risk 1 | Thesis: Pixxel has a plausible long-horizon opportunity narrative from an external article summary describing a Pixxel-led consortium winning an Indian EO constellation PPP, but that article is dated October 13, 2025 and was dropped by the 90-day recent evidence window, so it cannot support a current ranking thesis. Why now: Why now is weak because the only cited article summary in the reviewed sources are outside the 90-day evidence window, October 13, 2025 Caveats: The representative article for Pixxel is outside the recent evidence window and evidence recent evidence review shows kept_rows 0. No retained structured positive or negative rows are available. |
| 224 | Reliance Industries Limited lowweak | Opp 2 Risk 2 | Thesis: There is a possible long-horizon opportunity if Reliance, via Jio Platforms, advances its described LEO satellite communications ambitions, but the reviewed sources does not retain representative article details, or within the recent evidence window evidence to ground that as a current high-conviction thesis. Why now: Why now is weak because although the phase-2 rationale references articles, and: regarding LEO satellite communication plans, no or retained evidence are available and coverage data shows articles after recent evidence window of 0. Caveats: Phase-2 rationale suggests planning activity, not confirmed operating status, and cannot be cited as fact without /evidence. No representative articles or evidence are available after recent evidence window. Scores are constrained by insufficient retained evidence, not by a definitive neutral business view. |
| 225 | Remondo lowweak | Opp 2 Risk 2 | Thesis: Older context suggests a potentially differentiated Earth-observation approach, with a first mission planned in 2027 to demonstrate a partial aperture imaging system, but this falls outside the active evidence recent evidence window and is insufficient for a strong current rank. Why now: The only concrete article summary is dated February 23, 2026 and therefore outside the 90-day recent evidence window cutoff of March 29, 2026; it says Remondo plans to launch its first mission in 2027 to demonstrate PAIS, which is interesting for long-horizon monitoring but not strong enough for a current thesis. Evidence
Caveats: All dated evidence was dropped by the 90-day recent evidence filter. Only one older article is available, so corroboration is limited. |
| 226 | Rhea Space Activity lowweak | Opp 2 Risk 2 | Thesis: The membership rationale says Rhea Space Activity raised about $6 million in Series A financing for GPS-denied navigation software targeting military and intelligence customers, which would be a constructive long-horizon signal if confirmed by available evidence, but this screen contains no usable within the recent evidence window evidence or article. Why now: Why now is limited because no within the recent evidence window evidence were retained for ranking, so recency and durability cannot be tested. Caveats: Phase-2 membership rationale references, but no or available evidence row is provided in these reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. The financing claim cannot be elevated beyond low conviction without direct available evidence. |
| 227 | Rocket One, Inc. lowweak | Opp 2 Risk 2 | Thesis: Among this screen, Rocket One has the strongest contextual indication of a strategic pivot toward space/defense AI chips and nano-launch or nanosatellite enablement, which could become a long-horizon opportunity if later corroborated by direct execution evidence. However, these reviewed sources have no direct positive evidence inside the recent evidence window, so the thesis remains weak. Why now: Membership rationale cites articles, and: describing a renamed former biotech company pivoting toward space/defense AI chips and nano-launch or nanosatellite enablement, but coverage data still shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. unavailable in reviewed sources. Caveats: Context suggests strategic intent, not proven execution. No article are provided for cited membership-rationale articles. No direct evidence survive recent evidence filtering. |
| 228 | Rogue Space Systems lowweak | Opp 2 Risk 1 | Thesis: There is limited relevance support that Rogue Space Systems is an operating in-orbit servicing company, which is directionally compatible with a long-horizon commercial space opportunity view, but the evidence is only undated directory-style context and not direct positive operating proof. Why now: The only retained evidence is an undated external sector page listing Rogue Space Systems as an operating in-orbit servicing company, so the why-now is weak and recency is uncertain. Evidence
Caveats: Evidence is undated and explicitly not recency proof per reviewed sources policy. Same-article repeated rows are not independent confirmation. No direct evidence of contracts, funding, milestones, or setbacks is included. |
| 229 | RTX Corporation lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources' membership rationale references involvement in U.S. Space Force and missile-warning programs, which could support long-horizon opportunity, but no within the recent evidence window direct evidence or representative article summaries are available for scoring in this screen. Why now: Although the membership rationale references articles, and: the reviewed sources loads zero reviewed evidence after recent evidence filtering, so there is no directly scorable current catalyst from local evidence. Caveats: Very large article universe exists, but article count is not conviction. Membership support references potentially meaningful articles, but those summaries/evidence are not available here and therefore cannot be elevated into direct scoring evidence. |
| 230 | Sanyark Space Technologies lowweak | Opp 2 Risk 1 | Thesis: The reviewed sources places Sanyark Space Technologies in a spacetech accelerator among startups working on rocket propulsion, satellites, and space energy. That supports a possible early-stage opportunity setup, but the reviewed sources does not specify which activities belong to Sanyark itself and provides no direct evidence row or (: not provided in reviewed sources). Why now: There is no supported timing edge because the reviewed sources have zero direct evidence after recent evidence window and no dated article details beyond the structure. Caveats: Accelerator participation is weaker than company-specific funding or contract evidence. The article appears to describe a cohort rather than a company-specific event. No, quote, or direct event row is available. |
| 231 | Satellogic Inc. lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources membership rationale describes Satellogic as an Earth observation/geospatial company with constellation and monitoring contracts, which could be constructive over a 1 year+ horizon, but no available current evidence supports a stronger call. Why now: Why-now support is absent because coverage data shows zero evidence after recent evidence window. Caveats: Phase2 rationale cites 2026-04, and: but no representative articles or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Low score reflects missing current reviewed sources evidence rather than negative evidence. |
| 232 | SatixFy lowweak | Opp 2 Risk 2 | Thesis: Phase-2 rationale references SatixFy as an Israeli chipmaker acquired by MDA Space with first space-grade chips shipped, which may indicate strategic relevance, but there are no retained in-window evidence here. Why now: The reviewed sources includes no representative article or evidence row inside the 90-day recent evidence window, so there is no dated near-current catalyst to anchor a 1 year+ view from this screen alone. Caveats: No retained evidence after recent evidence window. Referenced acquisition/shipment facts are only in the phase-2 rationale here, not in cited retained evidence. |
| 233 | SatSure Analytics India Pvt. Ltd. lowweak | Opp 2 Risk 2 | Thesis: Reviewed evidence context indicates SatSure is developing a large Earth Observation AI model and received IN-SPACe Technology Adoption Fund support including a ₹24.6 crore grant, which could support longer-horizon capability building, but no direct post-recent evidence window evidence are available to validate timing, scale, or current business momentum in the next 1 year+ horizon. Why now: There is no reliable 'why now' catalyst in the available evidence. The reviewed sources notes support/article IDs were used for membership, but after the 90-day recent evidence filter there were 0 article IDs after recent evidence window and 0 evidence available, so recency is uncertain for any thesis. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs, and: but the reviewed sources does not provide or article summaries for citation. Without -bearing evidence, factual support is limited to reviewed sources-level membership rationale only. |
| 234 | SatVu lowweak | Opp 2 Risk 1 | Thesis: An external article says SatVu closed a £30m funding round, which is positive financing context, but that article is dated February 17, 2026 and was dropped by the 90-day recent evidence policy, so it cannot support a strong current opportunity ranking Why now: There is no usable within the recent evidence window evidence after filtering; the only cited article is older than the March 29, 2026 cutoff and therefore not timely support for a 1 year+ ranking under these reviewed sources' evidence policy. Caveats: The reviewed sources report zero kept rows after recent evidence window for SatVu. Older funding evidence exists but was dropped by policy, so recency is insufficient for a stronger score. |
| 235 | Scale AI lowweak | Opp 2 Risk 1 | Thesis: Membership rationale says Scale AI received a U.S. Space Force Golden Dome contract as part of an approximately $3.2 billion award group, which, if current and durable, could support a meaningful public-sector space/defense opportunity over a 1 year+ horizon. Why now: Why now is muted because the reviewed sources references support article in membership rationale, but no, article summary, or retained evidence after the 90-day filter are available to confirm timing or scope. Caveats: Despite 273 articles considered, coverage data shows articles after recent evidence window 0 and evidence after recent evidence window 0. The contract claim is only present in membership rationale citing article without a in the served reviewed sources. Opportunity score is kept low because the the evidence standard require direct positive evidence, not just membership inclusion. |
| 236 | Schaeffler AG lowweak | Opp 2 Risk 1 | Thesis: The reviewed sources rationale says Schaeffler planned a collaboration with Spire on satellite bus manufacturing and RF sensing, which suggests strategic adjacency to space systems, but there is no available within the recent evidence window direct evidence to underwrite a durable opportunity thesis. Why now: No surviving 90-day evidence are available despite 94 articles considered. The only support is the membership rationale reference to: but the reviewed sources provide no and no retained evidence. Caveats: Membership rationale is not sufficient directional proof. No direct positive or negative evidence survived the recent evidence window. Industrial-partner status versus core space-company status is unclear from the reviewed sources. |
| 237 | SEALCOIN AG lowweak | Opp 2 Risk 1 | Thesis: There is a hint of financing-related progress in space-based blockchain infrastructure, but the reviewed sources lack retained direct evidence strong enough to support a robust opportunity thesis. Why now: The membership rationale says SEALCOIN secured strategic investment for space-based blockchain infrastructure leveraging a satellite constellation, tied to article: but no or retained evidence are present after recent evidence window. Caveats: Only rationale-level description is available; no retained direct evidence row with is supplied. The business category fit is ambiguous in the reviewed sources itself. |
| 238 | Sidus Space Inc. lowweak | Opp 2 Risk 3 | Thesis: The membership rationale indicates Sidus Space operates LizzieSat satellites, manufacturing, and customer contracts, which could support a long-horizon operating-space-company thesis, but this screen includes no available within the recent evidence window article summaries or evidence to evaluate direction. Why now: Why now is weak because although the company had 44 considered articles, the reviewed sources show articles after recent evidence window = 0 and evidence after recent evidence window = 0, so the current business state is not evidenced here. Caveats: Phase-2 membership rationale references: and: but no or available evidence are provided. A large historical article universe should not be mistaken for conviction. No within the recent evidence window direct evidence is available for ranking. |
| 239 | Sift lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources hints at potential opportunity from Sift raising $42 million and building AI infrastructure for mission-critical hardware including space and defense, but no kept citable evidence or are provided here. Why now: Why now is weak because only article is referenced in the membership rationale, with no and no reviewed evidence to validate timing or materiality for the ranking horizon. Caveats: No article is available for article. Space exposure may be indirect rather than core. Coverage debug shows zero post-recent evidence window evidence. |
| 240 | Silicon Microgravity lowweak | Opp 2 Risk 2 | Thesis: There is modest theoretical opportunity because the reviewed sources' membership rationale says Silicon Microgravity received £500K in UK space funding, but no reviewed evidence row or citable article is supplied here. Why now: Why now is weak because the only support referenced is article: in the membership rationale, and the reviewed sources provide neither a nor a reviewed evidence row to substantiate timing beyond that summary. Caveats: No article is available for article Coverage debug shows zero post-recent evidence window evidence for ranking. Funding support alone, even if true, would not establish durable attractiveness without additional execution evidence. |
Risk view
Showing rows 61-80 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 61 | Xoople mediummedium | Opp 6 Risk 4 | Thesis: Article-level context also highlights structural Earth observation monetization difficulty and long procurement cycles, creating real commercialization risk even after the raise. Why now: Xoople closed a $130 million Series B on April 6, 2026/07 and articles say the capital is for building out its constellation; for a 1 year+ horizon, that financing can enable product and deployment progress, but the same dated coverage warns the market has historically been hard to monetize. Evidence
Caveats: Positive support is mostly supporting article context rather than positive evidence. Commercialization warning is article context, not a company-specific deterioration event. No direct customer, backlog, or launch milestone evidence is available. |
| 62 | AAC Clyde Space AB lowweak | Opp 3 Risk 3 | Thesis: There is no direct adverse evidence in the reviewed sources, so risk is moderate-low and mostly reflects inability to verify current contract progression, funding conversion, or execution status from available evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources' recent evidence review and coverage data show zero available evidence after recent evidence window despite the membership rationale referencing a material contract. Caveats: No current evidence is provided for Contract claim appears only in membership rationale, not in available direct evidence fields. No recency-confirmed follow-through evidence is available. |
| 63 | Aavuus mediummedium | Opp 5 Risk 3 | Thesis: Aavuus remains early-stage, and the evidence is supporting article context rather than direct positive events; the same article describes only pre-seed funding, which implies execution and scaling risk over a 1 year+ horizon. Why now: The opportunity is timely because the retained article is dated June 9, 2026 and describes a current financing and product build phase rather than stale background context. That said, recency comes from source date/article date, and evidence grounding is still article-level rather than direct fact/events., June 9, 2026 Evidence
Caveats: Evidence is weak context and supporting article context, not direct structured positive event evidence. No explicit customer, contract, revenue, or regulatory milestone is cited. Same article appears in multiple rows and is not independent confirmation. |
| 64 | Applied Atomics lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the reviewed sources' membership rationale describes it as a startup that emerged from stealth and raised only a $4M pre-seed, implying early-stage execution and financing risk, but this is not backed by available dated evidence in the ranking payload. Why now: There is no available dated evidence in the reviewed sources after recent evidence filtering, so recency-based ranking support is weak. Caveats: No representative articles or evidence are available after recent evidence filtering for ranking support. The phase2 membership rationale mentions a $4M pre-seed and Star Reacher Network, but the cited supporting articles are not provided with usable article summaries or evidence in these reviewed sources. |
| 65 | Astrolab lowweak | Opp 3 Risk 3 | Thesis: No direct negative evidence is available; the main risk in this ranking is evidence insufficiency rather than a documented adverse development. Why now: Why-now support is weak because coverage data shows no evidence after recent evidence window, so the cited lunar contract context cannot be refreshed from available evidence. Caveats: Phase2 rationale cites, and: but no representative article or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Private-company watch item rather than high-conviction ranked candidate. |
| 66 | Astroscale lowweak | Opp 5 Risk 3 | Thesis: No direct negative evidence is available. Remaining risk comes from the lack of post-recent evidence window evidence proving contract conversion, revenue realization, or mission execution scale. Why now: Why now is relatively constructive because a named partnership for on-orbit services can matter over a long strategic horizon, but exact timing and materiality cannot be validated from the reviewed sources because only membership rationale is visible. Caveats: Membership rationale references article ID: but the reviewed sources provide no or article summary. Relation counts are present in support metadata, but relations are context-only unless separately policy-gated. No direct positive or negative evidence arrays are populated. |
| 67 | Axelspace Corporation lowweak | Opp 3 Risk 3 | Thesis: No material negative evidence is present; risk is mainly execution and evidence-gap risk because current launch timing, deployment success, and monetization are not substantiated by the available reviewed sources evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources references a potentially important constellation expansion but provides no post-recent evidence window available evidence to confirm status or timing. Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Recency of constellation expansion cannot be validated from reviewed sources fields. |
| 68 | CAS Space lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the membership rationale describes IPO and reusable rocket development ambitions, both of which imply capital intensity and execution risk, but there is no available adverse evidence. Why now: There is no usable dated evidence available after recent evidence filtering, so the reviewed sources does not provide a clear timing catalyst. Caveats: The membership rationale references an IPO and Lijian-1 launch activity, but those source articles are not included with ranking-usable details in these reviewed sources. |
| 69 | CesiumAstro lowweak | Opp 5 Risk 3 | Thesis: The positive financing evidence is stale relative to the reviewed sources' 90-day recent evidence window. The article is dated February 14, 2026, which the reviewed sources say was dropped by the recent evidence filter, so there is no current-window evidence confirming whether financing momentum, backlog conversion, or product adoption continued Why now: There is no fresh catalyst inside the 90-day evidence window. The visible article was published on February 14, 2026 and is outside the cutoff date of March 29, 2026, so it is useful as background but weak for recency-sensitive ranking Evidence
Caveats: The visible positive article is outside the 90-day recent evidence window cutoff and was dropped from reviewed evidence. External supporting source context is allowed as evidence context but is not merged into primary data source. |
| 70 | ClearSpace mediummedium | Opp 7 Risk 3 | Thesis: Risks center on execution and evidence quality rather than explicit adverse news. The financing article carries internal chronology ambiguity because the page was published in 2026 but references a January 19, 2023 financing round, and the overall reviewed sources lack direct negative events, contract-performance data, or milestone completion proof. Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation. Evidence
Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated. |
| 71 | D-Orbit lowweak | Opp 4 Risk 3 | Thesis: No direct negative evidence is present. Risk remains moderate because the evidence base is only one cited article with no available direct events, leaving uncertainty on commercialization, timeline, and conversion from demonstration activity to durable revenue. Why now: Why now is the partnership/demo claim referenced in article ID, but the reviewed sources includes neither nor explicit article timing beyond the article ID prefix, limiting recency precision. Caveats: Opportunity rests on membership rationale rather than fully available direct evidence. Referenced article ID has no in the reviewed sources. Demo activity is not the same as proven commercial traction. |
| 72 | Dawn Aerospace mediummedium | Opp 7 Risk 3 | Thesis: Risk is non-trivial because the thesis depends on execution of a global rollout in a capital-intensive reusable space transportation market, but the reviewed sources does not show direct adverse events. Risk is therefore moderate rather than high. Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe. Evidence
Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context. |
| 73 | Earth Eye Co lowweak | Opp 2 Risk 3 | Thesis: Because the reviewed sources frames the company around surveillance/spy satellite activity rather than commercial traction, and provides no direct positive operating evidence, the name screens as a limited-visibility watchlist with modest evidence-based risk. Why now: Why now is weak because there are no available post-recent evidence window evidence, no article summaries, and no clear near- or long-horizon catalyst beyond generic association with a surveillance satellite. Caveats: Membership rationale cites article IDs and, but the reviewed sources provide no. Company is private and evidence coverage inside the recent evidence window is empty. |
| 74 | EDGX lowweak | Opp 4 Risk 3 | Thesis: Execution and financing risk remain material because the reviewed sources contain no kept direct evidence on follow-on funding, customer adoption, revenue conversion, or post-demo performance; technology demonstration does not by itself prove scale-up. Why now: The membership support references articles, and, implying a narrative of funding plus orbital demonstration, but active evidence remains empty after recent evidence filtering, limiting recency confidence. Caveats: In-orbit demo claim appears only in reviewed sources rationale, not available direct evidence. No evidence confirms whether the prior seed round falls within the current decision horizon relevance. No direct adverse evidence is present, but that is not proof of low fundamental risk. |
| 75 | Ellipsis Drive lowweak | Opp 4 Risk 3 | Thesis: Risk is mostly commercialization uncertainty. The reviewed sources does not provide direct negative evidence, but it also lacks direct available proof of revenue, customer conversion, or broader market adoption. Why now: Why now is the reviewed sources' claim that the company addresses a key EO data-processing bottleneck and has space-agency support, referenced to article ID: though no or timestamp detail was provided. Caveats: Claims come from membership rationale rather than direct evidence. Referenced article ID: lacks a reviewed sources. Support from agencies and target users is weaker than demonstrated contracted revenue. |
| 76 | EON Space Labs lowweak | Opp 1 Risk 3 | Thesis: The reviewed sources' clearest adverse context is that EON Space Labs was identified as one of the Indian private space companies affected by a PSLV failure, which could create execution, schedule, or financing ripple effects over a 1 year+ horizon, though the underlying article detail is not surfaced in the scoring evidence fields. Why now: Why now is stronger than for most names here because the phase2 rationale specifically ties EON Space Labs to a PSLV failure context via article: implying a concrete event rather than generic company context. However, conviction remains low because the reviewed sources omits the underlying event summary and dates in the evidence exposed here. Caveats: The adverse signal appears only in phase2 rationale, not in direct negative evidence. No article summary, quote, or timing detail is provided in the scoring fields. Impact magnitude on EON specifically cannot be quantified from these reviewed sources alone. |
| 77 | Eycore mediumweak | Opp 5 Risk 3 | Thesis: Risk remains moderate because the reviewed sources offers only one supporting article context and no direct positive event row beyond that summary, leaving unclear whether the satellite is generating revenue, delivering performance, or leading to follow-on orders. Why now: Why now is the dated first-satellite launch article from May 5, 2026, which is recent within the 90-day recent evidence window and relevant to a long-horizon de-risking story, though still early-stage. Evidence
Caveats: Evidence is supporting article context only, not a stronger structured positive event row. Single-article universe limits corroboration. No financing, customer, revenue, or performance follow-through evidence is provided. |
| 78 | GITAI mediummedium | Opp 6 Risk 3 | Thesis: Execution and commercialization risk remain meaningful because the retained evidence is still mainly company-provided article context and a technology demonstration milestone, not third-party validated contract wins, revenue conversion, or mission success; an undated directory listing that GITAI is 'operating' is weaker context and not recency proof. Why now: The key catalyst is recent and inside recent evidence window: on June 16, 2026, GITAI announced completion of the S3 flight model for an on-orbit servicing demonstration mission, which is directly relevant to a 1 year+ horizon because it may precede launch, demonstration, and downstream defense/commercial adoption over the next year. Evidence
Caveats: Primary evidence is from the company itself. No retained independent customer, contract, or revenue evidence is provided. The spaceindex.io entry is undated and should not be treated as recency proof. |
| 79 | Goonhilly Earth Station Ltd lowweak | Opp 3 Risk 3 | Thesis: The same reviewed sources rationale says Goonhilly is being acquired by Intuitive Machines, which can create integration, ownership, and business-state uncertainty over a 1 year+ horizon. Because no retained dated evidence are available, this risk is only moderately ranked. Why now: The only 'why now' available is the reviewed sources' statement that Goonhilly is being acquired by Intuitive Machines, cited in phase-2 support, and: but no, timestamps, or retained evidence are provided, so recency and sequence cannot be validated. Caveats: The reviewed sources rationale states Goonhilly has ground-station/COMSAT revenue and is being acquired by Intuitive Machines, tied to, and: but no or retained evidence are present. Coverage debug still shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Because chronology cannot be verified, transaction-state claims should be treated cautiously. |
| 80 | ICEYE highstrong | Opp 9 Risk 3 | Thesis: The reviewed sources does not show material adverse company-specific events; main risk is that most support is financing/context evidence rather than audited operating metrics or margins. Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon. Evidence
Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims. |